Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey

BMJ Paediatrics Open
Cristina Castro DíezStephanie Läer

Abstract

To characterise heart failure (HF) maintenance pharmacotherapy for children across Europe and investigate how angiotensin-converting enzyme inhibitors (ACE-I) are used in this setting. A Europe-wide web-based survey was conducted between January and May 2015 among European paediatricians dedicated to cardiology. Out of 200-eligible, 100 physicians representing 100 hospitals in 27 European countries participated. All participants reported prescribing ACE-I to treat dilated cardiomyopathy-related HF and 97% in the context of congenital heart defects; 87% for single ventricle physiology. Twenty-six per cent avoid ACE-I in newborns. Captopril was most frequently selected as first-choice for newborns (73%) and infants and toddlers (66%) and enalapril for children (56%) and adolescents (58%). Reported starting and maintenance doses varied widely. Up to 72% of participants follow formal creatinine increase limits for decision-making when up-titrating; however, heterogeneity in the cut-off points selected existed. ACE-I formulations prescribed by 47% of participants are obtained from more than a single source. Regarding symptomatic HF maintenance therapy, 25 different initial drug combinations were reported, although 79% select a regim...Continue Reading

References

Jan 1, 1994·Archives of Disease in Childhood·A M LevershaJ M Neutze
Aug 6, 1999·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·A S AdamsD Ross-Degnan
Apr 25, 2003·The New England Journal of Medicine·Alan W NugentUNKNOWN National Australian Childhood Cardiomyopathy Study
Apr 25, 2003·The New England Journal of Medicine·Steven E LipshultzSteven D Colan
Aug 11, 2004·European Heart Journal·José López-SendónUNKNOWN Task Force on ACE-inhibitors of the European Society of Cardiology
Dec 8, 2005·Herz·Claudia SommersAchim A Schmaltz
Feb 24, 2006·Paediatric Drugs·Kazuo Momma
Mar 17, 2007·Archives of Disease in Childhood·Hussain MullaHitesh C Pandya
Sep 13, 2007·JAMA : the Journal of the American Medical Association·Robert E ShaddyUNKNOWN Pediatric Carvedilol Study Group
Mar 7, 2008·American Journal of Pharmaceutical Education·Jolaine Reierson DraugalisCecilia M Plaza
Jul 30, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Karen E A BurnsUNKNOWN ACCADEMY Group
Aug 30, 2008·Clinical Cardiology·Martial M MassinHugues Dessy
Oct 8, 2009·Circulation. Heart Failure·Daphne T Hsu, Gail D Pearson
Oct 8, 2009·Circulation. Heart Failure·Daphne T Hsu, Gail D Pearson
Mar 27, 2010·Journal of the American College of Cardiology·Paul F KantorAndrew N Redington
Jul 14, 2010·Circulation·Daphne T HsuUNKNOWN Pediatric Heart Network Investigators
Aug 20, 2011·Paediatric Anaesthesia·Winnie Vogt, Stephanie Läer
Aug 15, 2012·Nephron. Clinical Practice·Arif Khwaja
Nov 26, 2013·The Canadian Journal of Cardiology·Paul F KantorUNKNOWN Children's Heart Failure Study Group
Jun 15, 2014·The Journal of Pediatrics·Joseph W Rossano, Robert E Shaddy
Aug 12, 2014·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Richard KirkRobert Weintraub
Feb 24, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Hae-Young Lee, Sang Hong Baek
Jul 19, 2016·Journal of Pediatric Endocrinology & Metabolism : JPEM·Rapeepun Chai-UdomVichit Supornsilchai
Oct 25, 2016·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Joseph W RossanoUNKNOWN International Society for Heart and Lung Transplantation
Oct 28, 2017·Archives of Disease in Childhood·Marijke van der MeulenSaskia N de Wildt

❮ Previous
Next ❯

Citations

Mar 2, 2021·Frontiers in Pediatrics·Muhammad FaisalUNKNOWN LENA Consortium

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

R
Studio
EvaSys

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.